Cross-Sector entity
Boston Scientific is most often covered alongside Medtronic, which appears in 5 of these 9 stories. That works out to roughly 0.3 stories per week across a 188-day span. The busiest single day carried 3. pharma accounts for 4 of the 9 tracked stories, while 4 other categories carry the remainder.
9 verified stories tracked
Last mentioned: Sep 2, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Boston Scientific is most often covered alongside Medtronic, which appears in 5 of these 9 stories. That works out to roughly 0.3 stories per week across a 188-day span. The busiest single day carried 3. pharma accounts for 4 of the 9 tracked stories, while 4 other categories carry the remainder. The tracked stories average 4.2 original sources each. Boston Scientific appears in 9 tracked Cross-Sector stories published from February 27, 2026 through September 2, 2026. 56% of these stories carry negative sentiment.
Computed from the 9 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific. Shared-story counts are live from our verified record — not editorial picks.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Public breach disclosure
Novocure publicly reported the cyberattack, disclosing that internal records of more than 1,400 U.S. patients were exposed.
Investigation remains unresolved
SecurityWeek reports no known cybercrime group has claimed responsibility; full scope, nature, and financial impact remain unknown.
No group claims responsibility
SecurityWeek reports no known cybercrime group has taken credit for the attack, and data breach status remains unclear.
Disclosure and market reaction
Company announces global operational disruption, including order processing and shipping systems; shares fall about 4% in morning trading. Evercore ISI estimates a 600-700 bps Q3 revenue impact if recovery mirrors Stryker's three-week timeline.
Public disclosure and stock decline
The company activates incident-response procedures, works with third-party cybersecurity specialists, and files an SEC statement. Shares fall roughly 4% in morning trading.
Cyber incident detected
Boston Scientific detects a cybersecurity incident affecting some IT systems.
Unauthorized access occurs
Novocure says unauthorized access to certain information systems occurred in mid-August 2026, exposing internal patient records.
Incident response activated
Novocure activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Secondary Notice
Pomerantz reinforces the filing highlights to ensure broad investor awareness.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Initial Legal Notice
Pomerantz LLP issues the first public call for shareholders to join the class action.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
SEC 8-K Filing
BSX files a Form 8-K under Item 8.01 (Other Events), potentially triggering market reaction.
Earnings Report
Boston Scientific reports Q4 2025 financial results and provides 2026 guidance.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Novocure disclosed a mid-August cyberattack that exposed internal records of more than 1,400 U.S. oncology patients, along with provider contact details and employee job titles. The company said treatment devices were not accessed and that it expects no material financial impact. For healthcare IT and compliance leaders, the incident is another compelling case study in breach response, data classification, and regulatory risk.
Source: CNA
A cybersecurity incident at medical device maker Boston Scientific has disrupted global order processing and shipping systems. Security teams are watching for ransomware involvement and the scope of any data breach as recovery begins. The attack is the latest in a string of healthcare sector cyber incidents.
Boston Scientific's August 25 cyberattack has disrupted global order processing and shipping, creating clinical and financial uncertainty for the medical device maker. Evercore ISI estimates a 600-700 basis point hit to Q3 revenue if recovery follows Stryker's roughly three-week timeline. The company has not yet determined whether the incident will be material.
Source: SecurityWeek
A cybersecurity incident at Boston Scientific has disrupted order processing and shipping globally, threatening hospitals and surgical centers reliant on its devices. Analysts warn of a 600-700 bps Q3 revenue hit if recovery matches Stryker's three-week timeline. Health leaders must assess supply chain and patient care risks.
Source: CNA · Sahil Pandey
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Pomerantz LLP has issued a formal notice regarding a class action lawsuit against Boston Scientific Corporation (BSX), alleging potential securities fraud. The litigation focuses on whether the medical technology giant made misleading statements regarding its product pipeline or regulatory compliance during the class period.
Source: pr-inside.com · pr-inside.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
